EMA (EU)
EVENT
Real-world data collection in Duchenne muscular dystrophy: Joint Heads of Medicines Agencies (HMA) / European Medicines Agency (EMA) multistakeholder workshop
Published: 9/25/2026Detected: 9/18/2026
Summary preview
Promotes structured collaboration to address gaps in real-world data (RWD) collection for Duchenne muscular dystrophy, with the goal of generating meaningful evidence on medicine effectiveness and safety.
Get the full analysis, free
Create a free account to see the complete summary, key takeaways, and why this matters for your products, and to get alerts like this by email.
Create free accountrare_diseases
pediatrics
neurology
clinical
safety
#real-world data
#RWD
#real-world evidence
#RWE
#Duchenne muscular dystrophy
Official Source Document Source Verified
Access the original document directly from EMA.
More from EMA (EU)
- Mandatory use of ISO/ICH E2B(R3) individual case safety reporting in the EU: hands-on training course using the EudraVigilance system10/12/2026
- First European Medicines Agency (EMA) - International Society for Cell and Gene Therapy (ISCT) bilateral meeting10/12/2026
- Q&A clinic on eXtended EudraVigilance Medicinal Product Dictionary (XEVMPD) service - October 202610/8/2026
- PMS Q&A Clinic on Product User Interface (PUI) and Application Programming Interface (API) – October 202610/8/2026
- SPOR and XEVMPD status update webinar - Q4 202610/7/2026